Empagliflozin in Patients with Chronic Kidney Disease
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index; 19 of the 28 sources its claims cite were checked for support.
Abstract
Trial of empagliflozin in a broad chronic kidney disease population.
Overview
CoChat Summary
TL;DR
Empagliflozin 10 mg daily reduced the risk of the composite of kidney disease progression or cardiovascular death in the EMPA-KIDNEY randomized trial of 6609 people with chronic kidney disease. Benefits were consistent with and without diabetes and across the eGFR range studied, with no clear increase in serious adverse events overall.
Key findings
- The primary composite outcome occurred in 432 of 3304 patients (13.1%) on empagliflozin versus 558 of 3305 (16.9%) on placebo; hazard ratio 0.72 (95% CI 0.64 to 0.82; P<0.001).
- All-cause hospitalizations were fewer with empagliflozin: 24.8 versus 29.2 hospitalizations per 100 patient-years; hazard ratio 0.86 (95% CI 0.78 to 0.95; P=0.003).
- There was no statistically significant effect on hospitalization for heart failure or cardiovascular death (4.0% vs 4.6%; hazard ratio 0.84, 95% CI 0.67 to 1.07; P=0.15) or death from any cause (4.5% vs 5.1%; hazard ratio 0.87, 95% CI 0.70 to 1.08; P=0.21).
- Empagliflozin slowed eGFR decline: the between-group difference in chronic slope was 1.37 ml/min/1.73 m² per year (95% CI 1.16 to 1.59), and urinary ACR was reduced by 19% (95% CI 15% to 23%).
Methods
- Multicenter, international, randomized, double-blind, placebo-controlled trial conducted at 241 centers in 8 countries; 6609 participants were randomized to empagliflozin 10 mg once daily or matching placebo.
- Eligible adults had CKD with eGFR ≥20 to <45 ml/min/1.73 m², or eGFR ≥45 to <90 ml/min/1.73 m² with urinary ACR ≥200 mg/g; patients with or without diabetes were eligible, and those with polycystic kidney disease or a kidney transplant were excluded.
- Primary analysis used intention-to-treat Cox regression adjusted for age, sex, prior diabetes, eGFR, urinary ACR, and region; key secondary outcomes were multiplicity-adjusted, and eGFR slope was assessed with shared parameter models.
Limitations
- The paper states that the lower-than-expected cardiovascular event rate reduced statistical power for secondary or tertiary cardiovascular outcomes.
- Evident from the text: the trial was stopped early for efficacy at an interim analysis, so follow-up was relatively short (median 2.0 years).
- Evident from the text: some subgroup estimates, especially for lower albuminuria strata, were limited by fewer primary outcome events.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
10 Valid · 0 Not valid · 4 Not checked · 40 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A prespecified subgroup analysis from a trial of the SGLT2 inhibitor dapagliflozin in patients with CKD and a urinary ACR of at least 200 mg/g, found that kidney benefits extended to patients without diabetes”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Conclusions
What the sources say
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Abstract (p. 1437) specifies a urinary albumin-to-creatinine ratio of 200–5000 mg/g. Figure 2 identifies diabetes status as a prespecified subgroup, and the Discussion states that kidney-protective effects extended to participants with chronic kidney disease without type 2 diabetes. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [12] Wheeler DC Stefansson BV Jongs N Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial Lancet Diabetes Endocrinol 2021 9 1 22 31 10.1016/S2213-8587(20)30369-7 33338413 source
- Supportedcites [13] Staplin N Roddick AJ Emberson J Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials EClinicalMedicine 2021 41 101163 10.1016/j.eclinm.2021.101163 34765951 PMC8571171 source
The Results (Eligible trial characteristics) identify DAPA-CKD as a dapagliflozin trial in patients with CKD and urinary ACR of 200–5000 mg/g. The Results (Relative effects of SGLT-2 inhibitors) report that the effect on kidney disease progression in the CKD trial appeared similar with and without diabetes; the References identify the underlying DAPA-CKD work as a prespecified analysis. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The effect of SGLT2 inhibition on kidney disease progression or cardiovascular death seen in the present trial is quantitatively similar to that seen in two other large placebo-controlled trials in CKD populations.6,7”
§ Empagliflozin in Patients with Chronic Kidney Disease > Discussion
What the sources say
- Supportedcites [6] Perkovic V Jardine MJ Neal B Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy N Engl J Med 2019 380 24 2295 2306 10.1056/NEJMoa1811744 30990260 source
The Methods identify CREDENCE as a placebo-controlled trial in patients with type 2 diabetes and albuminuric CKD. Table 2 reports a hazard ratio of 0.70 for its primary composite of kidney disease progression or renal or cardiovascular death. This supports the citation’s role as one of the two earlier CKD trials; the paper does not itself compare its result with EMPA-KIDNEY. (LLM, conf=0.88)
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Efficacy Outcomes table reports that DAPA-CKD was a placebo-controlled trial in patients with chronic kidney disease and found a lower risk of the kidney-progression or cardiovascular-death composite with dapagliflozin (hazard ratio, 0.61). The cited paper supplies one of the two trial results; the statement that its effect is quantitatively similar to EMPA-KIDNEY is the citing authors’ comparison, not a finding attributed to this paper alone. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“or death from any cause (4.5% vs 5.1%)”
- Also stated in: § Primary and Secondary Outcomes · plain
“or on death from any cause (hazard ratio, 0.87; 95% CI 0.70 to 1.08; P=0.21)”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The rates of serious adverse events were broadly similar in the two groups.”
- Also stated in: § Safety Outcomes and Adverse Events · hedged
“There was no apparent evidence that empagliflozin increased the incidence of serious adverse events overall, or in any particular MedDRA system organ class (Table S8).”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Safety Outcomes and Adverse Events · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were fewer hospitalizations from any cause in the empagliflozin group (0.86; 0.78 to 0.95, P=0.003)”
- Also stated in: § Primary and Secondary Outcomes · plain
“there were significantly fewer first and subsequent hospitalizations from any cause in the empagliflozin group (24.8 versus 29.2 hospitalizations per 100 patient years: hazard ratio, 0.86; 95% CI 0.78 to 0.95, P=0.003)”
- Also stated in: § Discussion · plain
“Risk of hospitalization for any cause was also reduced by 14%.”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
17 more claims
Create a free account to see all 54 claims and every source verdict.
- It may state two separate claims as one. 24
- Probably not a substantial claim. 16
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozintreated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [115]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozin-treated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [128]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Dedicated kidney outcomes trials in people with CKD and type 2 diabetes have shown that the SGLT2 inhibitors empagliflozin, canagliflozin, and dapagliflozin have beneficial effects on slowing progression of CKD and CV outcomes in this population (139-141).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [141]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, SGLT2i have been studied specifically among patients with CKD with or without T2D in 3 completed primary kidney outcome trials (CREDENCE[15], DAPA-CKD[16], and EMPA-KIDNEY[17]), which showed benefit for both a significant reduction in the primary kidney outcomes and cardiovascular outcomes [18,19].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“The DAPA-CKD and FIDELIO trials enrolled patients with eGFR ≥25 mL/min/1.73 m2 and the EMPA-KIDNEY trial enrolled patients with eGFR ≥20 mL/min/1.73 m2; results demonstrated that dapagliflozin, finerenone and empagliflozin are effective and safe in these patients, although safety data are lacking for initiating therapy below these thresholds [16,17,22].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493 · cited 1×
“…kidney disease with increased levels of albuminuria, large placebo-controlled trials have shown that renin-angiotensin system (RAS) inhibitors, 3–5 sodium-glucose cotransporter 2 (SGLT2) inhibitors, 6,7 and the non-steroidal mineralocorticoid receptor antagonist finerenone 8,9 all reduced the…”
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 2×
“6,7 The CREDENCE trial of canagliflozin required all participants to have type 2 diabetes and a urinary ACR of at least 300 mg/g, and excluded patients with an eGFR of less than 30 ml per minute per 1.73 m 2 .”
InfluentialLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618 · cited 3×
“…with an estimated GFR (eGFR) below 30 ml per minute per 1.73 m 2 or on how these benefits might vary among the wider range of patients with CKD. 7,12,13 This multicenter international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess…”
InfluentialThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Cited by
Items 2,101–2,200 of 2,656
Ray, G. M., Winters, A., Lopez, M., Bos, A. J., Bermudez, S. R., & Anderson, J. R. (2025) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaf082
Bharati, J., Bosch, N. A., & Upadhyay, A. (2026) · BMC Nephrology · doi:10.1186/s12882-026-05111-9 · Cited by 1
“Empa-gliflozin and dapagliflozin, the two most commonly used SGLT2-inhibitors in clinical practice [3], reduce the risk of major adverse kidney outcomes by 30–40% over 2–3 years in clinical trials including individuals with CKD, with or without diabetes [4, 5].”
New and Emerging Nonimmunosuppressive Drug Therapies for Primary Adult Glomerular Diseases
Mushailov, V., & Radhakrishnan, J. (2025) · Kidney Medicine · doi:10.1016/j.xkme.2025.101133 · Cited by 2
Wang, K., Wang, W., Niu, J., Liu, Y., Wang, Z., Wang, Z., Han, H., Sun, Y., Liu, X., & Ge, H. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05161-1 · Cited by 1
“A similar result was also obtained in the EMPA-Kidney trial, illustrating that empagliflozin improved renal and cardiovascular outcomes in patients with CKD with or without diabetes [41].”
Kitada, M., Toyoda, M., Sekine, O., Suzuki, D., Okada, Y., Morita, Y., Nishimura, H., Satoh, H., Kamiya, H., Takamura, T., et al. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70173 · Cited by 1
“The results of three large randomized controlled trials: CREDENCE 10 , DAPA-CKD 11 , and EMPA-KIDNEY trials 13 , clearly demonstrated that SGLT2is provide signi fi cant bene fi ts for renal composite outcomes.”
InfluentialEyadiel, L., & Modarressi, T. (2025) · Journal of Cardiac Failure - Intersections · doi:10.1016/j.yjcafi.2025.08.015
Yee, K. M., Sagim, E., Leong, C. W., Liew, I., Mahathar, M. N., Zulhuda, N. A., Ahmad, S., Baharin, N. A., Miryala, N., Gaddamedi, N., et al. (2025) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1614
Htoo, P. T., Tesfaye, H., Schneeweiß, S., Wexler, D. J., Glynn, R. J., DiCesare, E., Freedman, A., Schmedt, N., Shay, C. M., Paik, J. M., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70195 · Cited by 1
Chen, M., Cao, X., An, K., Wang, Y., Yan, Q., Men, Y., Wang, H., He, M., Du, S., Gu, Z., et al. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-025-01584-3
Worsening heart failure events in adults with mild-to-moderate chronic kidney disease
Ye, L., Girouard, M. P., Go, A. S., Liu, J. Y., Parikh, R., Tan, T. C., Lee, E. S., Sun, G. E. C., Halaseh, R., Bhatt, A. S., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.107290
Zaza, G. (2025) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001788
Novikova, M. S. N., Minushkina, L. O., Allazova, S. S. A., Zateyshchikov, D. A., Boeva, O. I., Kotenko, O. N. K., Vinogradov, V. E., Em, S., Antsiferov, M. B., Koteshkova, O. M. K., et al. (2025) · Kardiologiia · doi:10.18087/cardio.2025.9.n2952
Heart Failure With Comorbidities
Li, Y., & Liang, M. (2025) · Cardiology Discovery · doi:10.1097/cd9.0000000000000172 · Cited by 1
Association between caffeine and the eGFR dip after initiation of SGLT2 inhibitors in adult patients
Kisley, Z., Kalishman, A. J., Memon, A. A., Dhindsa, S., Edwards, J. C., Mosman, A. K., Lentine, K. L., Kunnath, P., Wood, E. A., & Miyata, K. N. (2025) · Physiological Reports · doi:10.14814/phy2.70638
“…of evidence indicating that SGLT2i not only improve glycemic control but also confer significant benefits in terms of kidney function, cardiovascular outcomes, and mortality reduction (Heerspink et al., 2020; Herrington et al., 2023; McMurray et al., 2019; Packer et al., 2020; Zinman et al., 2015).”
Inhibitors of sodium-glucose cotransporter: When wasting fuel is sought and beneficial to health
Alhenc‐Gelas, F. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103742
Teplan, V., Petejová, N., & Valkovský, I. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.079
Abdelaziz, M., Hassib, M. A., Fouad, T., Said, I. F., Shokr, A. M., Metwally, A. E., Abdelaziz, A. S., Elbeny, A. M., Elkhouly, A. A., Soltan, M. E., et al. (2025) · Cureus · doi:10.7759/cureus.95876
“However, most studies have excluded patients receiving kidney replacement therapy (KRT) or kidney transplant (KT) recipients, leaving a gap in the literature regarding the safety, efficacy, and clinical outcomes of SGLT2i use in these populations [6-8].”
Santamaría, R., Escobar, C., Aranda, U., Palacios, B., Capel, M., Hernández, I., Cebrián, A., Alcázar, R., & Gorostidi, M. (2025) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2025.501340 · Cited by 1
Hu, Z., Jin, W., Lou, S., & Zhang, L. (2025) · Renal Failure · doi:10.1080/0886022x.2025.2578413 · Cited by 1
“Recent large-scale clinical trials have validated the cardiorenal benefits of finerenone and SGLt2i [17,18,28–30], positioning these agents as guideline-recommended additions to Soc. mechanistic synergy between finerenone and SGLt2i, supported by preclinical and clinical evidence, suggests enhanced…”
Martinetti, C., George, B., Schachtner, T., Ruschitzka, F. T., Frank, M., & Rho, E. (2025) · Journal of CardioRenal Medicine · doi:10.3390/jcrm1010005
Research Progress on Clinical Treatment Standards for Membranous Nephropathy
常, 婷. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1482322
López, J. P., Capote, P. A. C., Pozo, A. H., Castilla‐Guerra, L., Fernández‐García, J. C., Olmo, R. F., & Huete, M. J. E. (2025) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2025.501359 · Cited by 1
Pharmacologic Therapy for Type 2 Diabetes
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch04
Sodium-Glucose Cotransporter-2 Inhibitors
Berlie, H. D. (2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch10
Pharmacologic Therapy for Type 1 Diabetes
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch01
Medications for the Management of Chronic Kidney Disease
Tran, E. (2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch25 · Cited by 1
Chronic Kidney Disease and Risk Management
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch18
Kimura, K., TAKAGI, Y., Harada, M., Ueda, S., Minamisawa, M., Sonoda, K., Oiwa, A., Yazaki, Y., Sakurai, S., Tomita, T., et al. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01822-8
Diabetes Mellitus: Promising Clinical Research in a Time of Political Uncertainty
Beninger, P. R. (2025) · Clinical Therapeutics · doi:10.1016/j.clinthera.2025.10.010
Neumiller, J. J., & Tuttle, K. R. (2025) · Kidney360 · doi:10.34067/kid.0000000989
Matsui, M., Nishimoto, M., Uemura, T., Kitamura, S., Tato, W., Tsushima, H., Kosugi, T., Eriguchi, M., Samejima, K., Mita, M., et al. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04649-4
“However, current treatments for CKD are largely limited to certain evidence-based medications such as renin–angiotensin system inhibitors and sodium–glucose co-transporter-2 inhibitors [40–42].”
Maharaj, A., Bidhesi, S., Grover, D., et al. (2025) · Cureus · doi:10.7759/cureus.98140
“…use in patients with chronic kidney disease and HF. Findings from studies evaluating the effects of SGLT2 (dapagliflozin [13] and empagliflozin [14]) inhibitors on chronic kidney disease and cardiovascular outcomes consistently demonstrate a reduced mortality risk among patients receiving…”
Diagnosis and treatment of coronary artery disease in patients with chronic kidney disease
Dod, R., Yadav, H., & Jovin, I. S. (2025) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2025.2597772
“EMPA-KIDNEY trial randomized 6609 CKD patients with no history of CAD to empagliflozin or placebo and demonstrated a reduction in cardiovascular mortality and progression of kidney disease, suggesting a benefit in primary prevention of cardiovascular disease as well as in secondary prevention [81].”
Diabetes Mellitus and the Increased Risk of Acute Kidney Injury Following Acute Coronary Syndrome
Shah, M. U., Squires, P. E., Hills, C. E., & Lee, K. (2025) · Diabetology · doi:10.3390/diabetology6120148
Wang, Q., Liu, D., Liu, J., Tang, P., Wang, X., Liu, Q., Fan, B., Hu, M., & Meng, L. (2025) · Intelligent Medicine · doi:10.1016/j.imed.2025.06.002
Lee, L. Y., Epstein, A. J., Chatterjee, S., et al. (2025) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2025.25167
Boosting CONFIDENCE in Combination Therapy for Diabetic Kidney Disease in Asia
Tang, M., & Kalim, S. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000959
Disease modification in immunoglobulin A nephropathy
Barratt, J. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf259
Zieliński, M., Michalak, O., Ruszczak, M., & Cybulski, M. (2025) · Molecules · doi:10.3390/molecules30244681
“Empagliflozin was also studied in the same context, and the results were similar [23], thereby introducing these antidiabetic agents fully to the nephrology field.”
Johannes, C. B., Coleman, C. I., Kovesdy, C. P., Khan, A. M., ZIEMIECKI, R. M., Layton, J. B., Vizcaya, D., Liu, F., & Oberprieler, N. G. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01825-5 · Cited by 1
Iwakura, T. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf385
“This degree of improvement is comparable to, and does not appear inferior to, the slope changes re-ported in major SGLT2 inhibitor trials such as DAPA-CKD [3 ] and EMPA-KIDNEY [4 ], as well as the prespecified subgroup analysis from DAPA-CKD [5 ].”
Elshayeb, M., Abdulgalil, A. E., El-Husseini, A. A., Elhadedy, M. A., Sally, S. M., Refaie, H., Mortada, W. I., Nabieh, K. A., & Sobh, M. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf384 · Cited by 3
“Several studies have demonstrated the effectiveness of sodium–glucose co-transporter 2 inhibitors ( SGLT2is) in slowing CKD progression in both diabetic and non-diabetic patients [3 , 4 ].”
Maladie rénale chronique diabétique
Gosset, C., Rigalleau, V., Esnault, V. L. M., & Foussard, N. (2025) · EMC - Endocrinologie - Nutrition · doi:10.1016/s1155-1941(24)46692-4 · Cited by 1
Bridging Cardiorenal and Hepatic Disease: The Emerging Role of SGLT2 Inhibitors in Cirrhosis
Alkasabrah, O. Y., Ibrahim, S., Hafeez, A., Chaudhry, M. Q., Jajja, F. A., Raval, M., Jain, H., Maheta, D., Agrawal, S. P., Frishman, W. H., et al. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001141 · Cited by 3
Sethi, B. K., Mehta, A., Dasgupta, A., Chawla, M. S., Deka, N., Agarwal, N., Mazumder, C., Ghosh, I., Gala, V., Muchhala, S., et al. (2025) · Cureus · doi:10.7759/cureus.99023
“…role in the multidisciplinary management of DKD, supported by randomized controlled trial (RCT) evidence demonstrating improvements in glycemic control along with clinically meaningful delays in DKD progression and reductions in end-stage renal disease and cardiovascular mortality [15,30].”
InfluentialLi, L., Tain, Y., Chien, S., Kuo, H., & Hsu, C. (2025) · Clinical and Translational Science · doi:10.1111/cts.70405
Bogomolov, A. N., Николаевна, К. О., Kozlov, K. L., & Golikova, E. N. (2025) · Russian Journal of Geriatric Medicine · doi:10.37586/2686-8636-4-2025-546-556 · Cited by 1
Vadia, R., Vandendriessche, E., Mahieu, E., Meeus, G., Pottelbergh, G. V., Jouret, F., Retat, L., Card-Gowers, J., Jadoul, M. Y., Vankeirsbilck, A., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-098420
Chen, J., Tsai, M., Ho, W.-Y., Fang, Y.-W., Chen, M., & Hsiao, C.-C. (2025) · The American Journal of Medicine · doi:10.1016/j.amjmed.2025.12.011 · Cited by 1
Romano, G., Ferraccioli, G., & Colussi, G. (2025) · Frontiers in Nephrology · doi:10.3389/fneph.2025.1713215 · Cited by 1
Cozzolino, M. G., Magagnoli, L., & Ciceri, P. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2608857
“The EMPA-KIDNEY trial demonstrated significant reductions in kidney disease progression and cardiovascular death across a broad non-diabetic CKD population [10], while newer analyses from 2024 confirmed benefits even in patients with lower levels of proteinuria [4].”
Sohn, M., Nam, S., Nauck, M. A., & Lim, S. (2024) · Figshare · doi:10.6084/m9.figshare.26157034
Tanaka, A., Shibata, H., Imai, T., Yoshida, H., Miyazono, M., Takahashi, N., Fukuda, D., Okada, Y., Teragawa, H., Suwa, S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23812512
Lee, S. E., Yoo, J., Kim, B.-S., Choi, H. S., Han, K., & Kim, K.-A. (2023) · Figshare · doi:10.6084/m9.figshare.22608833
Tanaka, A., Shibata, H., Imai, T., Yoshida, H., Miyazono, M., Takahashi, N., Fukuda, D., Okada, Y., Teragawa, H., Suwa, S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23812515
Additional file 1 of Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis
Chen, J.-Y., Pan, H.-C., Shiao, C.-C., Chuang, M.-H., See, C. Y., Yeh, T.-H., Yang, Y., Chu, W.-K., & Wu, V. (2024) · Figshare · doi:10.6084/m9.figshare.26633337
Tanaka, A., Shibata, H., Imai, T., Yoshida, H., Miyazono, M., Takahashi, N., Fukuda, D., Okada, Y., Teragawa, H., Suwa, S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23812518
Roddick, A., Wonnacott, A., Webb, D. R., Watt, A., Watson, M. A., Staplin, N., Riding, A., Lioudaki, E., Kuverji, A., Kossi, M. E., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24439354
Lyu, Y. S., Hong, S., Lee, S. E., Cho, B. Y., & Park, C.-Y. (2024) · Figshare · doi:10.6084/m9.figshare.25231187
Htoo, P. T., Tesfaye, H., Schneeweiß, S., Wexler, D. J., Everett, B. M., Glynn, R. J., Schmedt, N., Koeneman, L., Déruaz‐Luyet, A., Paik, J. M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25194735
Wang, C.-A., Lin, L.-C., Chen, J.-Y., Wang, W.-J., & Wu, V. (2024) · Figshare · doi:10.6084/m9.figshare.26945832
Pestka, D. L., Murphy, D. P., Huynh, P., Rechtzigel, J. A., Kjos, S., Ellich, L. M., Kaplan, A. N., Taylor, B. C., Atwood, M. A., Polsfuss, B. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26663458
Wang, C.-A., Lin, L.-C., Chen, J.-Y., Wang, W.-J., & Wu, V. (2024) · Figshare · doi:10.6084/m9.figshare.26945835
Chronische Niereninsuffizienz bei Typ-2-Diabetes – die stille Bedrohung einer Multisystemerkrankung
Günes-Altan, M., & Schmieder, R. (2025) · Diabetes aktuell · doi:10.1055/a-2624-4700
Santamaria, R., Escobar, C., Aranda, U., et al. (2025) · Nefrología · doi:10.1016/j.nefro.2025.501414
Robbins, S., Grandominico, J. M., Tayal, N. H., et al. (2025) · Researchers Journal of Internal Medicine · doi:10.63495/8067749
Ramsbacher, N., & Neumiller, J. J. (2025) · American Diabetes Association eBooks · doi:10.2337/9781580408486-references
The Initial Effect of SGLT 2 Inhibitors on GFR: A Hemodynamic Perspective – Single-Center Experience
Sezen, M., & Akgür, S. (2025) · Uludağ Üniversitesi Tıp Fakültesi Dergisi · doi:10.32708/uutfd.1716421 · Cited by 1
Баранова, Д. С., & Шамелашвили, К. Л. (2025) · Bulletin of Problems Biology and Medicine · doi:10.29254/2523-4110-2025-4-179/addition-101-103
Adeva‐Andany, M. M. (2025) · World Journal of Nephrology · doi:10.5527/wjn.v14.i4.110990
SGLT2 inhibitors in polycystic kidney disease (PKD): current evidence and future perspectives
Lombardi, M., Batazzi, A., Martini, B., Mehmetaj, A., & Michelassi, S. (2025) · Giornale di Clinica Nefrologica e Dialisi · doi:10.33393/gcnd.2025.3674
Montilla, P. J., Crisostomo, A. C., Cunanan, E. L., Lara-Valenzona, M. R. D., Leon, D. F. D., Encarnacion, P. J., Estabillo, A. P., Gonzales, C. J., Mallari-Catungal, M., Tiongco, R. H. P., et al. (2025) · Journal of Medical Economics · doi:10.1080/13696998.2025.2602361
Gosmanov, A. R. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf690
Kidoguchi, S., Kitada, K., Morishita, A., Tsuji, Y., Ohsaki, H., Yamazaki, D., Morikawa, T., Konishi, Y., Kobara, H., Yokoo, T., et al. (2025) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2025.12.006
Lau, D. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.12.008
Reprint of: Chronic Kidney Disease in Diabetes: A Clinical Practice Guideline
Tobe, S. W., BAJAJ, H. S., Tangri, N., Jain, R., Pham, T., Beaudin, V., & McFarlane, P. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.12.004
Mazzeo, L., Sellasie, S. W., Pecchioli, C., Perna, P., Zaccaria, S., Sperti, P., Nardone, I., Giurato, L., Della-Morte, D., Caprio, M., et al. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02756-5 · Cited by 1
Lee, J., Park, S., Kim, E., Park, J.-Y., Rhee, M., Hughes, J. W., Ko, S., Kwon, O., & Lee, E. Y. (2026) · Journal of Korean Medical Science · doi:10.3346/jkms.2026.41.e44 · Cited by 2
SGLT2 Inhibitors and Long-Term Outcomes After AKI
Wannakittirat, A., Nimkietkajorn, V., Thanapongsatorn, P., Chaijamorn, W., Sorose, N., Leewongworasingh, A., Yimsangyad, K., Lumlertgul, N., Peerapornratana, S., & Srisawat, N. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.103752
“The primary studies on SGLT2i, including the EMPA-KIDNEY and DAPA-CKD trials, 26,27 had mean follow-up durations of $ 2 years, and the effects of SGLT2is on the progression of kidney disease or death from cardiovascular causes became apparent after 1 year.”
The cardiovascular evaluation of candidates for living kidney donation
Chauhan, K., Garg, N., Wolff, M. R., Mandelbrot, D. A., & Dhingra, R. (2026) · Transplantation Reviews · doi:10.1016/j.trre.2025.100990
Yang, C., Denig, P., Chepulis, L. M., Paul, R. G., Shin, J. H., Gansevoort, R. T., & Vart, P. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70421 · Cited by 2
Sodium-glucose cotransporter-2 inhibitors and sepsis: a story with two tails or with one tail?
Afşar, B., Afşar, R. E., Tuttle, K. R., & Lentine, K. L. (2026) · Inflammopharmacology · doi:10.1007/s10787-025-02091-4 · Cited by 1
Bhaduri, G., BHATTACHARYYA, S., Mukherjee, S., & Gokalani, R. A. (2026) · Acta Diabetologica · doi:10.1007/s00592-025-02636-7
Gautier, P., Lafaurie, M., Bouisset, F., Delmas, C., Cherbi, M., Lhermusier, T., Elbaz, M., & Montastruc, F. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvaf009
“19,20 Low initiation in the CKD subgroup may be explained by a concern about causing a worsening of renal function by adding a functional component to pre-existing CKD.”
Wu, C.-Y., Lai, C., Ho, C., Wu, Y.-C., Liao, K., Wang, J.-J., Wang, D.-C., & Liang, F. (2026) · Journal of Diabetes Research · doi:10.1155/jdr/1437417 · Cited by 1
Hypertension in Diabetes: Numbers or Outcomes?
Koufakis, T., & Doumas, M. N. (2026) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00785-2
Sugawara, H., Yoshida, K., Saito, C., et al. (2026) · Hypertension Research · doi:10.1038/s41440-025-02536-x
Chanchanayothin, T., Klomwong, C., Saisri, T., Panudom, S., Chaiyamahapurk, S., Theerasuwipakorn, N., Siranart, N., Pajareya, P., Songsirisuk, N., Pravarnpat, C., et al. (2026) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2026.101873
“Prior trials, such as DAPA-CKD[23] and EMPA-KIDNEY[24], have shown that SGLT2i reduce renal function decline and cardiovascular events even in non-diabetic individuals.”
Duni, Α., Tsavourelou, P., Triantafyllidou, M., Gkika, L., Georgopoulos, C., Stamellou, E., Κίτσος, Α., & Dounousi, E. C. (2026) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2025.1759340 · Cited by 1
Ye, N., & Cheng, H. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s540082
“Severely reduced renal function will also restrict the application of guideline-recommended medical therapy (GDMT) in managing these diseases.”
Zieg, J. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2620099
“Similarly, empagliflozin significantly reduced the risk of composite outcome of progression of kidney disease or cardiovascular death in adults with CKD including 817 individuals with IgAN [42].”
Loukianov, М. М., Васильевна, К. А., Smirnov, А. А., Smirnov, А. А., Okshina, Е. Y., Кямиловна, М. Д., & Drapkina, O. M. (2026) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2025-3268
de Moraes, T. P., Moura, A. F., Sposito, A. C., et al. (2026) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2025-0231pt
Makino, H., Kasahara, M., Takashima, R., Kasama, S., Ozu, N., Park, H., Chen, Q., Tsuruya, K., Tochiya, M., Omura‐Ohata, Y., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70485 · Cited by 2
Lindhardt, R. B., Rasmussen, S. B., Machado, M., et al. (2026) · BMJ Digital Health & AI · doi:10.1136/bmjdhai-2025-000172
Navarrete, R. E. T., Fernandes, J., Fonseca, I. M., Silvano, J., Martins, L. S., & Sa, J. R. (2026) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2026.100302
Rever, J., Khalid, N., Kulig, C. E., & Girgis, J. (2026) · Healthcare · doi:10.3390/healthcare14030318
Elavarasan, S., Soundararajan, K., Kovvuri, S. R., Venuturumilli, R., Anita, M., Naganathan, K., & Gopukumar, S. T. (2026) · KIDNEYS · doi:10.65327/kidneys.v15i1.602
Tian, Z., Sternberg, M., Willerding, J. M., Schmidt-Ott, K. M., Melk, A., & Schmidt, B. (2026) · medRxiv · doi:10.64898/2026.01.28.26345070
Metadata
- Authors
- The EMPA-KIDNEY Collaborative Group
- Corresponding author
- The EMPA-KIDNEY Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-01-12
- Volume
- 388
- Issue
- 2
- Pages
- 117-127
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7614055
- OpenAlex
- W4308183941
- Cited by
- 2,754
- References
- 26
- Citations by year
- 2026: 727 · 2025: 759 · 2024: 734 · 2023: 520
- FWCI
- 321.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nd)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Docusalut (Conselleria de Salut i Consum del Govern de les Illes Balears) (submittedVersion, cc-by-nd)
- Hispana (submittedVersion, cc-by-nd)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Bristol Research (University of Bristol) (submittedVersion)
- Explore Bristol Research (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- Boehringer Ingelheim
- Eli Lilly and Company
- NIHR Biomedical Centre, Oxford
- Health Data Research
- Medical Research Council (MC_UU_00017/3 & MR/R007764/1)
- Kidney Research UK (MR/R007764/1)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- empagliflozin, chronic kidney disease, kidney disease progression, cardiovascular mortality, heart failure hospitalization, SGLT2 inhibitors, EMPA-KIDNEY trial, estimated glomerular filtration rate, diabetes mellitus
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Cardiovascular Diseases, Creatinine, Diabetes Mellitus, Type 2, Glomerular Filtration Rate, Glucosides, Humans, Kidney, Disease Progression, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.